Seelos Makes Progress on ALS Study Trial

Seelos expects to launch an expanded access program for the treatment later this quarter.

Seelos Therapeutics Inc. (Nasdaq: SEEL) announced the completion of enrollment of its registrational Phase II/III trial studying the investigational treatment SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) on the HEALEY ALS Platform Trial.

Trehalose is a naturally occurring disaccharide that is widely distributed throughout the biological world and is found in plants, algae, fungi, yeasts, bacteria, insects, and other invertebrates.

“The full enrollment of this study is a significant milestone for Seelos. We look forward to releasing the topline data later this year and initiating the expanded access program later this quarter,” said Raj Mehra Ph.D., chairman and CEO of Seelos.

Seelos said that its Phase II/III trial (NCT05136885) enrolled 160 participants with either familial or sporadic ALS for a double-blind placebo-controlled trial. Participants were randomized 3:1 (drug:placebo), with the primary endpoint measuring the change from baseline on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at 24 weeks. Secondary endpoints include change from baseline in slow vital capacity, muscle strength, quality of life measurements as well as additional signs of disease progression.

Seelos’ planned expanded access program (EAP) is fully funded by a grant from the National Institute of Neurological Disorders and Stroke under the ACT for ALS. Under this EAP, Seelos plans to enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS who do not qualify for other ongoing clinical trials, thus offering these patients an experimental treatment that they may not otherwise have access to.

Ketamine Study

Seelos is also known for its ketamine studies, and last week the company reported that it had dosed the first patients in an ethnobridging study in healthy adult Japanese and non-Asian subjects to compare the safety and pharmacokinetic profiles of SLS-002 (intranasal racemic ketamine).

Seelos consulted and received endorsement from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and from the U.S. Food and Drug Administration (FDA) to conduct this Phase I ethnobridging study.

“This ethnobridging study is an important first step as we begin evaluating the potential for SLS-002 in patients globally,” Mehra said. “Our market research suggests a high unmet global need for a therapy with both antidepressant and antisuicidal effects.”

Study SLS-002-103 will measure elements such as dosage and administration, sample size, inclusion and exclusion criteria, endpoints, and blood sampling. Seelos expects that data from this study will help inform the inclusion of Japanese subjects in the design of a future global trial in patients with major depressive disorder (MDD) at imminent risk of suicide.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.


  • Veronica McKall

    March 7, 2023 at 1:56 am

    This was great, I have been researching for a while now, and I think this has helped. Have you ever come across Health Natural Centre ALS disease HERBAL FORMULA (just google it). It is a smashing one of a kind product for reversing Lou Gehrig’s disease completely. Ive heard some decent things about it and my buddy got amazing success with it.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 1 day

Goodness Growth Earnings Benefit from Arizona Exit, Minnesota Market Changes

@GreenMarketRpt – 1 day

Kentucky Becomes 38th State to Legalize Medical Marijuana

@GreenMarketRpt – 1 day

Clever Leaves Ekes Past Expectations, Losses Rise

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.